These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 25051328)

  • 1. Healthcare resource use and costs of privately insured patients who switch, discontinue, or persist on anti-muscarinic therapy for overactive bladder.
    Ivanova JI; Hayes-Larson E; Sorg RA; Birnbaum HG; Berner T
    J Med Econ; 2014 Oct; 17(10):741-50. PubMed ID: 25051328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.
    Ng DB; Espinosa R; Johnson SJ; Walker D; Gooch K
    J Med Econ; 2017 Dec; 20(12):1272-1280. PubMed ID: 28805473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder.
    Pelletier EM; Vats V; Clemens JQ
    Am J Manag Care; 2009 Mar; 15(4 Suppl):S108-14. PubMed ID: 19355799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Potentially Inappropriate Use of Antimuscarinic Medications on Healthcare Use and Cost in Individuals with Overactive Bladder.
    Suehs BT; Davis C; Franks B; Yuran TE; Ng D; Bradt J; Knispel J; Vassilakis M; Berner T
    J Am Geriatr Soc; 2016 Apr; 64(4):779-87. PubMed ID: 27059714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of buprenorphine/naloxone dosing impact on treatment duration, resource use and costs in the treatment of opioid-dependent adults: a retrospective study of US public and private health care claims.
    Khemiri A; Kharitonova E; Zah V; Ruby J; Toumi M
    Postgrad Med; 2014 Sep; 126(5):113-20. PubMed ID: 25295655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: Retrospective analysis of a UK General Practice prescription database.
    Wagg AS; Foley S; Peters J; Nazir J; Kool-Houweling L; Scrine L
    Int J Clin Pract; 2017 Oct; 71(10):. PubMed ID: 28906080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder.
    Chancellor MB; Migliaccio-Walle K; Bramley TJ; Chaudhari SL; Corbell C; Globe D
    Clin Ther; 2013 Nov; 35(11):1744-51. PubMed ID: 24091072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of discontinuing overactive bladder medications.
    Brubaker L; Fanning K; Goldberg EL; Benner JS; Trocio JN; Bavendam T; Jumadilova Z
    BJU Int; 2010 May; 105(9):1283-90. PubMed ID: 19912189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overactive bladder medication adherence when medication is free to patients.
    Sears CL; Lewis C; Noel K; Albright TS; Fischer JR
    J Urol; 2010 Mar; 183(3):1077-81. PubMed ID: 20092838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system.
    Rashid N; Lin AT; Aranda G; Lin KJ; Guerrero VN; Nadkarni A; Patel C
    J Med Econ; 2016 Jun; 19(6):568-75. PubMed ID: 26766553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of central nervous system, cardiovascular and overall co-morbidity burden in patients with overactive bladder disorder in a real-world setting.
    Asche CV; Kim J; Kulkarni AS; Chakravarti P; Andersson KE
    BJU Int; 2012 Feb; 109(4):572-80. PubMed ID: 21777361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada.
    Hakimi Z; Nazir J; McCrea C; Berling M; Fatoye F; Ramos B; Wagg A
    J Med Econ; 2017 Jun; 20(6):614-622. PubMed ID: 28286993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative persistence and adherence to overactive bladder medications in patients with and without diabetes.
    Johnston S; Janning SW; Haas GP; Wilson KL; Smith DM; Reckard G; Quan SP; Bukofzer S
    Int J Clin Pract; 2012 Nov; 66(11):1042-51. PubMed ID: 23067028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US.
    Cohen R; Skup M; Ozbay AB; Rizzo J; Yang M; Diener M; Chao J
    J Med Econ; 2015 Jun; 18(6):447-56. PubMed ID: 25728698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
    Wagg A; Compion G; Fahey A; Siddiqui E
    BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates.
    Nitz NM; Jumadilova Z; Darkow T; Frytak JR; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S130-9. PubMed ID: 16161386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Burden of venous leg ulcers in the United States.
    Rice JB; Desai U; Cummings AK; Birnbaum HG; Skornicki M; Parsons N
    J Med Econ; 2014 May; 17(5):347-56. PubMed ID: 24625244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of pharmacological treatments for overactive bladder from the perspective of the UK National Health Service.
    Nazir J; Posnett J; Walker A; Odeyemi IA; Hakimi Z; Garnham A
    J Med Econ; 2015 May; 18(5):390-7. PubMed ID: 25488631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact on healthcare resource usage and costs among Medicaid-insured schizophrenia patients after initiation of treatment with long-acting injectable antipsychotics.
    Bera R; Offord S; Zubek D; Lau G; Lin J; Baker RA; Karson C
    J Med Econ; 2013; 16(4):522-8. PubMed ID: 23360177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis.
    Eby EL; Wang P; Curtis BH; Xie J; Haldane DC; Idris I; Peters AL; Hood RC; Jackson JA
    J Med Econ; 2013; 16(4):529-38. PubMed ID: 23363330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.